Clinical Trials for Limb Reduction Defect
There is currently 1 ongoing clinical trial investigating treatment options for limb reduction defect. This trial focuses on evaluating the long-term safety of tazemetostat in patients who have previously participated in tazemetostat clinical trials and are continuing to benefit from the treatment. The trial is being conducted in France and Poland.
Clinical trial locations
- France
- Poland
Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials
This clinical trial is designed to monitor the long-term safety of tazemetostat, a medication given as a film-coated tablet taken by mouth. The study specifically focuses on patients who have already been treated with tazemetostat in previous clinical trials and have shown positive responses to the treatment.
Main inclusion criteria:
- You must currently be benefiting from tazemetostat treatment
- You must be receiving tazemetostat either alone or combined with other medications as part of an earlier clinical trial
- Your life expectancy needs to be more than 3 months
- Your blood tests must show adequate bone marrow, kidney, and liver function, as well as appropriate blood cell counts and clotting factors
- Women who can become pregnant must have a negative pregnancy test and agree to use both a highly effective birth control method (such as implants, injections, birth control pills, or IUDs) and a barrier method (such as condoms) during treatment and for 6 months afterward
- Men must either have had a successful vasectomy and use condoms, or ensure that they and their partner use effective contraception during treatment and for 3 months after the last dose
Main exclusion criteria:
- Patients not currently receiving tazemetostat in a previous clinical study
- Those who experienced severe side effects during previous tazemetostat treatment
- Patients unable to comply with long-term safety monitoring requirements
- Those who have developed medical conditions that make continued treatment unsafe
- Patients who have withdrawn consent from their previous tazemetostat study
- Those who developed progressive disease while on tazemetostat
- Patients participating in other clinical trials at the same time
Trial focus: The main goal of this study is to evaluate the long-term safety of tazemetostat in patients who continue to benefit from the medication. Researchers will monitor any side effects that occur and assess how well patients tolerate the medication over an extended period. The study will track various health measures, including blood cell counts, kidney function, and liver function. Additionally, researchers will monitor how long patients survive while receiving the treatment. This is an open-label study, meaning all participants will receive the active medication without any placebo. The study is planned to continue until September 2025.
Investigational drug: Tazemetostat is a medication that belongs to a class of drugs called EZH2 inhibitors. It works by blocking the EZH2 protein, which plays an important role in controlling gene expression and cancer cell growth. Tazemetostat is primarily used in treating certain types of lymphomas and solid tumors, particularly in patients with specific genetic mutations. The medication represents an innovative approach in targeted therapy and is given as film-coated tablets for oral use.
Summary
Currently, there is one clinical trial available for patients with limb reduction defect. This trial is being conducted in two European countries: France and Poland. The study focuses specifically on evaluating the long-term safety of tazemetostat in patients who have already participated in previous tazemetostat clinical trials and continue to show clinical benefit from the treatment.
The trial is notable for its focus on long-term safety monitoring rather than initial treatment effectiveness. It is designed for patients who are already responding well to tazemetostat and aims to track any side effects that may develop over extended use. The study requires participants to have adequate organ function and, for those of childbearing potential, to follow strict contraception guidelines. The trial is expected to continue until September 2025, providing valuable information about the sustained safety profile of tazemetostat in this patient population.